INTRODUCTION

It is estimated that about 30 million adults live with high serum cholesterol levels (≥240 mg/dl) (Benjamin et al., 2019). High cholesterol has been associated with poor cardiovascular health. Elevated serum cholesterol is correlated with atherosclerosis and significant morbidity and mortality (Parish et al., 2012), however, vascular pathology alone does not fully explain the benefits of cholesterol-lowering therapies in reducing the risk of developing fatal arrhythmias that originate in...
the heart (Buber et al., 2012). Studies have shown that a high cholesterol diet is associated with an increase in intercellular cholesterol in cardiac myocytes with effects on intracellular Ca\(^{2+}\) cycling (Huang et al., 2004; Jacobson et al., 1985), but it is not entirely clear whether elevated cholesterol affects other aspects of cardiac physiology.

ATP-sensitive potassium (K\(_{\text{ATP}}\)) channels are known to play an important role in the heart during metabolic stress (Flagg et al., 2010; Foster & Coetzee, 2016). K\(_{\text{ATP}}\) channels are activated when intracellular ATP concentration falls or MgADP rises (Lederer & Nichols, 1989; Nichols & Lederer, 1990; Noma, 1983). During myocardial ischemia, K\(_{\text{ATP}}\) activation serves to shorten the cardiac action potential, reduce Ca\(^{2+}\) entry into the cell, and cause a characteristic ST-segment elevation in the ECG (Baczkó et al., 2005; Claus et al., 2002). Conversely, increasing K\(_{\text{ATP}}\) activity using pinacidil or ischemia and reperfusion (Cole et al., 1991; Suzuki et al., 2001). Inhibition of K\(_{\text{ATP}}\) with sulfonylureas or by genetic deletion (Kubota et al., 1993; Li et al., 2000; Nichols & Lederer, 1990). Given the importance of K\(_{\text{ATP}}\) in response to cardiac stress, adjusting its expression is expected to have consequences on cardiovascular health.

In the mouse heart, the sarcolemmal K\(_{\text{ATP}}\) channel is a hetero-octomeric protein complex composed of four inward rectifier (Kir6.2; Kcnj11) pore-forming subunits combined with four sulfonylurea receptor subunits (SURx; Abccx) (Chutkow et al., 2001; Li et al., 2000; Nichols & Lederer, 1990). Sarcolemmal K\(_{\text{ATP}}\) channels are also essential for ischemic preconditioning where brief bouts of ischemia serve to protect the heart during a subsequent long-term ischemic event (Gross & Auchampach, 1992; Wojtovich et al., 2013). Given the importance of K\(_{\text{ATP}}\) in response to cardiac stress, adjusting its expression is expected to have consequences on cardiovascular health.

In mouse atrial cardiomyocytes, SUR1 (Abcc8) is the sulfonylurea receptor present, while in ventricular myocytes, SUR2A (Abcc9) is the major accessory subunit (Chutkow et al., 2001; Flagg et al., 2008). We recently showed that the canonical histone deacetylase inhibitor (HDACi), trichostatin A (TSA), causes a significant increase in the expression of SUR2 in HL-1 cardiomyocytes (Fatima et al., 2015).

TSA is typically thought to increase gene expression by inhibiting histone deacetylases leading to an increase in histone acetylation that promotes unwinding of chromatin to increase transcription factor accessibility. In our previous study, we found a TSA-dependent increase in histone H3 acetylation (Lys9) at the SUR2 promoter consistent with this proposed model of epigenetic regulation (Fatima et al., 2015). Surprisingly, we also observed that cellular cholesterol was reduced in TSA-treated HL-1 cells and that cholesterol inhibited the effect of TSA on K\(_{\text{ATP}}\) subunit expression without affecting histone acetylation (Fatima et al., 2015). TSA has been shown to reduce cholesterol accumulation in mutant Neimann Pick Type C1 (NPC) fibroblasts and SH-SY5Y cells (Nunes et al., 2013; Pipalia et al., 2011). Taken together, these previous results suggest that in addition to increasing histone acetylation, TSA may deplete HL-1 cells of cholesterol thereby stimulating a cholesterol-sensitive signaling pathway that regulates K\(_{\text{ATP}}\) channel expression.

One well-known cholesterol-sensitive transcription factor is the sterol response element (SRE) binding protein or SREBP (Horton et al., 2002). When cholesterol levels in the cell are sufficient, SREBP interacts with a protein complex containing sterol cleavage activating protein (SCAP) and Insig, sequestering SREBP in the endoplasmic reticulum (ER). When cholesterol levels in the cell fall, reduced cholesterol in the ER causes the SCAP/SREBP complex to dissociate from Insig and translocate to the Golgi, where SREBP can be cleaved by site-1 protease (S1P). Cleavage of SREBP allows the transcription factor to translocate to the nucleus, bind SREs, and activate transcription of target genes (Wang et al., 1994). Therefore, a decrease in intracellular cholesterol is predicted to activate SREBP signaling, while an increase in intracellular cholesterol inhibits SREBP-dependent gene transcription.

There are two different genes encoding SREBP isoforms—SREBP1 and SREBP2 (Brown & Goldstein, 1999). SREBP1 has two splice variants (SREBP-1a and SREBP-1c) that are typically associated with regulating the genes required for fatty acid and cholesterol synthesis, while SREBP2 typically regulates expression of enzymes needed for cholesterol synthesis and transport. However, it is increasingly recognized that SREBP proteins can regulate the expression of genes other than those involved in cholesterol or lipid homeostasis. For example, a recent study demonstrates a role for SREBP in regulating the parasympathetic response of chick cardiomyocytes through regulation of G-protein gated inward rectifying K\(^{+}\) channels expression (Park et al., 2008). Interestingly, \textit{in silico} analysis of the SUR2 promoter suggests that it contains a SRE (Philip-Couderc et al., 2008), leading to the hypothesis that SREBP may be the cholesterol-sensitive mediator.
linking TSA treatment, cholesterol depletion, and $K_{ATP}$ subunit expression.

In this study, we tested the hypothesis that TSA increases SUR2 expression through a mechanism that requires cholesterol depletion and involves activation of SREBP signaling. The results show that increased SUR2 expression correlates with decreased levels of cellular cholesterol, cleavage, and translocation of SREBP1. Moreover, we show that inhibition of SREBP signaling suppresses the effects of TSA on gene expression. Taken together, these results reveal a novel cholesterol-dependent mechanism that regulates $K_{ATP}$ subunit expression and may contribute to poor cardiovascular health associated with hypercholesterolemia.

2. MATERIALS AND METHODS

2.1 Cell culture

All cells were maintained in a humidified incubator with 5% CO$_2$ at 37°C. HL-1 cardiomyocytes were cultured on tissue culture vessels coated with gelatin (0.02% w/v) and fibronectin (0.5% v/v; Sigma) and were maintained in supplemented Claycomb media as previously described (Elcarpio et al., 1998; Fatima et al., 2012, 2015). COSm6 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) supplemented with 10% Fetal Bovine Serum and (100 µg/ml) Penicillin/Streptomycin. Cells were passaged using 0.05% trypsin/0.02% EDTA. In some experiments, HL-1 cells were treated with Claycomb media supplemented with Trichostatin A (TSA), cholesterol (250× cholesterol lipid concentrate, Gibco cat no. 12531-018), or PF429242 (Sigma cat no. SML0667) at concentrations and durations indicated in the text.

2.2 Imaging experiments

In all imaging experiments, HL-1 cardiomyocytes on glass coverslips were fixed with 4% paraformaldehyde (FD NeuroTechnologies, cat no. PF101), quenched with 0.15% glycine, and labeled for either cholesterol quantitation or SREBP-1 immunolocalization. Cells examined for cholesterol quantitation were stained with filipin (0.05 mg/ml; Cayman chemical, cat no. 70440), PicoGreen (Invitrogen, cat no. P11496), and FBS 10% in PBS for 2 hr. Cells examined for SREBP-1 localization were blocked and permeabilized with 10% FBS, 0.1% Triton X-100 in PBS at RT for 1 hr. Following blocking, cells were incubated with antibodies specific to SREBP-1 (1:50; Abcam, cat no. ab28481) in 0.1% triton ×100 at 4 degrees overnight. To visualize SREBP-1 antibody localization, secondary Alexa Fluor 488 conjugated anti-rabbit IgG 2° antibody (1:500 Invitrogen) with 0.1% triton ×100 and DAPI in PBS at RT for 1 hr. Labeled coverslips were mounted with VECTASHIELD (Vector, cat no. H-1000) on glass microscope slides and sealed with nail polish. To visualize filipin staining, cells were exposed to UV light (ex: 370–420 nM) and fluorescence (em: 410–460 nM) was collected on a Nikon Eclipse Ti2 microscope using a 40x oil objective. To visualize SREBP-1 localization, cells were excited at 495 nM and fluorescence was collected on a Nikon A1 resonant scanning confocal system. Image quantitation was performed on reconstructed Z-projections (0.5 µM between each slice for the z stack) encompassing the entire volume of the cell. Images were quantitated using Fiji and the mean fluorescence intensity was normalized to time 0 hr and the nuclear fluorescence was normalized to control (Schindelin et al., 2012).

2.3 Protein isolation and Western blot analysis

To isolate proteins, cells were lysed with RIPA buffer (Sigma, cat no. R0278), supplemented with PMSF and protease inhibitors (Roche, cat no. 11836153001). Protein concentration was estimated using the BCA assay (Thermo Scientific). Protein was separated using polyacrylamide gel electrophoresis (4–15%) and transferred to a PVDF membrane (Bio-Rad Inc.). The membrane was blocked in 5% milk and incubated with anti-SREBP antibody (1:250; Santa Cruz, cat no. sc-365513) overnight at 4 degrees followed by antimouse IgG secondary antibody (cat no. A11008) in TBS-T for 1 hr. The signal was observed using SuperSignal West Dura Extended Duration substrate (Thermo Scientific) and images captured on the Bio-Rad ChemiDoc imager and analyzed using Fiji (Schindelin et al., 2012).

2.4 Quantitative RT-PCR

mRNA expression was assessed using qPCR as described previously (Fatima et al., 2015). Briefly, RNA was extracted from HL-1 cells using Quick-RNA MiniPrep (Zymo Research) and treated with DNase to remove residual genomic DNA. RNA concentration and quality were determined using a NanoDrop 2000 Spectrophotometer (Nanodrop Technologies Inc.). cDNA was synthesized from 1ug of RNA using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems Inc.). qPCR was performed on a CFX384 Real-Time System C1000 Thermal Cycler (Bio-Rad Inc.) using Taqman probe and primer pairs obtained from Applied Biosystems, Inc. Reactions were performed in triplicate. Relative fold changes (normalized to $HPRT$) were reported as $2^{-\Delta\Delta Ct}$, where $\Delta Ct = \Delta Ct_{\text{drug}} - \Delta Ct_{\text{notreatment}}$. 
2.5 | Luciferase assay

Transcriptional activation of the SUR2 upstream regulatory sequence by SREBP signaling was assessed using luciferase assays. Briefly, the 470 bp sequence immediately upstream of the SUR2 transcription start site was amplified by PCR and cloned into the pGluC Mini-TK Gaussia luciferase reporter vector (New England Biolabs; cat no. N8086). cDNA encoding SREBP-1a (pcDNA3.1-2xFLAG-SREBP-1a) was a gift from Timothy Osborne (Addgene plasmid #26801; http://n2t.net/addgene:26801; RRID:Addgene_26801) (Toth et al., 2004). A predicted SRE, homologous to that found in SREBP target genes like PCSK9 was identified in the SUR2 promoter using Genomatix software (Cartharius et al., 2005). We also deleted three nucleotides (TCA) within the site using the Q5 site-directed mutagenesis kit (New England BioLabs cat# E0554S) resulting in the construct pGluc SUR2_SRE_Mut-Luciferase. COSm6 cells were plated in a 24-well plate at a concentration of 50,000 cells per well. Following overnight incubation, each well was transfected with 500 ng pcDNA3.1-2xFLAG-SREBP-1a and 500 ng pGluC SUR2-Luciferase or pGluC SUR2_SRE_Mut-Luciferase using Lipofectamine 3000 (Thermo Scientific). Luciferase activity was assessed using the pierce luciferase assay glow kit (Thermo Scientific), post-transfection. Total luciferase activity of each well was normalized to protein level. Protein concentration was determined using a BCA assay (Thermo Scientific).

2.6 | Data analysis and statistics

Data were analyzed using GraphPad software to determine significance between multiple treatments, we used a one-way ordinary ANOVA with a Bonferroni post hoc test. A Student’s t test was used to determine statistical significance between two groups. Unless otherwise stated, standard error of the mean is shown.

3 | RESULTS

We previously showed that the canonical HDACi, trichostatin A (TSA), causes a significant increase in expression of the SUR2 (Abcc9) subunit of the $K_{\text{ATP}}$ channel. Interestingly, we found that cholesterol concentration was reduced in TSA-treated cells and addition of cholesterol to the culture medium inhibited the effect of TSA without affecting histone acetylation (Fatima et al., 2015). This result implied that there may be a cholesterol-sensitive mechanism activated by HDACis that is required for increased expression of SUR2 in addition to the transcriptional effects of increased histone acetylation. Therefore, we tested the hypothesis that TSA increases SUR2 expression through a mechanism that requires cholesterol depletion and activation of the cholesterol sensitive SRE binding protein (SREBP) signaling pathway.

3.1 | TSA treatment causes a decrease in cellular cholesterol and an increase in SUR2 mRNA expression

To elucidate the role of cholesterol in regulating SUR2 expression, we first measured the time course of cellular cholesterol depletion and gene expression changes in TSA-treated HL-1 cardiomyocytes. To assess cellular cholesterol, we labeled cells with the fluorescent antibiotic, filipin (Leventhal et al., 2001). As expected if cellular cholesterol concentration falls, we observed a marked decrease in filipin staining following TSA treatment that is inhibited when exogenous cholesterol was also added to the media (Figure 1a). In parallel experiments, we measured SUR2 expression using qRT-PCR (Figure 1b). We found that SUR2 mRNA expression is inversely correlated with the time-dependent decrease in the cellular cholesterol concentration as estimated by filipin fluorescence and the increase in SUR2 expression. TSA alone or in the presence of cholesterol had little or no effect on SUR1 expression (data not shown). Taken together, the temporal correlation of SUR2 expression with the decrease in filipin staining suggests that cholesterol depletion in the presence of TSA is the principal catalyst for changes in SUR2 expression and supports the hypothesis that a previously unrecognized cholesterol-sensitive mechanism may regulate $K_{\text{ATP}}$ subunit expression.

3.2 | TSA treatment causes cleavage of SREBP in HL-1 cells

SREBP is a cholesterol-sensitive transcription factor that is known to upregulate genes involved in cholesterol and fatty acid biosynthesis (Brown & Goldstein, 1999; Horton et al., 2002; Wang et al., 1994). For example, proprotein convertase subtilisin/kexin type-9 (PCSK9) is an important regulator of cholesterol uptake and is a well-characterized SREBP target gene (Jeong et al., 2008; Joseph & Robinson, 2015). In support of the hypothesis that TSA induces SREBP signaling, we observed a marked increase in PCSK9 mRNA expression in TSA-treated cells, which was inhibited by cholesterol (Figure 2a). Because histone acetylation is associated with increases in gene expression through epigenetic mechanisms, we first determined whether TSA activated SREBP by increasing its expression. SREBP-1 mRNA was not increased (Figure 2b),
therefore, we next examined whether SREBP signaling was activated in TSA-treated HL-1 cells. When cholesterol levels in the cell are sufficient, SREBP is localized to the endoplasmic reticulum. If cellular cholesterol falls, SREBP is trafficked to the Golgi, where it is cleaved to form the active SREBP transcription factor (Wang et al., 1994). Indeed, in western blots we observe a significant increase in the presence of the SREBP cleavage product (~68 kDa) indicating cleavage and a corresponding decrease in the amount of full-length SREBP-1 in TSA-treated cell lysates compared to control (Figure 2c–e). Moreover, when cells are treated with TSA and cholesterol, SREBP-1 cleavage is inhibited, consistent with the conclusion that the TSA-dependent fall of cellular cholesterol leads to cleavage and activation of SREBP signaling.

3.3 | TSA treatment causes trafficking of SREBP to the nucleus of HL-1 cells

Cleavage of SREBP frees the truncated protein so that it can traffic to the nucleus and bind SREs in the genome (Wang et al., 1994; Yokoyama et al., 1993). Because TSA increases SREBP cleavage, it is expected that there will be more SREBP protein localized to the nucleus. To test this, we performed immunolocalization studies to determine whether TSA increased the amount of SREBP protein found in the nucleus (Figure 3). Indeed, HL-1 cells treated with TSA showed a significant increase in SREBP-1 localization to the nucleus when compared to either control cells or cells treated with both TSA and cholesterol. This result demonstrates that in addition to cleavage in the presence of TSA, SREBP

**FIGURE 1** TSA-dependent increase in SUR2 expression mirrors the time-dependent reduction in cellular cholesterol. (a) Representative micrographs of HL-1 cells following treatment with either TSA or TSA+Cholesterol for up to 72 hr. Cells were labeled with the fluorescent antibiotic filipin (0.05 mg/ml) to estimate cellular cholesterol concentration. (b) Summary data showing an inverse correlation of the cellular cholesterol (filipin staining intensity; n = 4 biological replicates, 14–62 per time point) and SUR2 subunit expression (n = 3; p < 0.05 ANOVA; Bonferroni Post hoc test *p < 0.05, 0 hr vs. TSA 72 hr) measured in parallel experiments in cells treated with TSA or TSA+cholesterol for the indicated duration. The addition of cholesterol inhibited both the decrease in cellular cholesterol and the increase in SUR2 expression.
protein translocates to the nucleus where it can stimulate
gene transcription.

3.4 | SREBP increases expression from the SUR2 promoter

We next sought to determine whether SREBP-1 can in-
crease transcription from the SUR2 promoter. To ac-
complish this, we cloned 470 bp of the noncoding region
upstream of the SUR2 gene transcription start site into a
plasmid encoding a Gaussia luciferase reporter gene. In

silico analysis of this segment of the upstream regulatory
sequence of the mouse SUR2 gene using Genomatix soft-
ware (Cartharius et al., 2005) predicted the presence of
an SREBP binding site, similar to the SRE in the PCSK9
gene (Hyun et al., 2008). This is also in agreement with
similar data reporting the presence of an SREBP binding
sequence in the promoter of both human and rat SUR2
genes (Philip-Couderc et al., 2008) (Figure 4a). Previous
studies have shown that deletion of the TCA nucleotides
of the consensus SRE can interfere with SREBP binding
and transactivation (Magañ & Osborne, 1996), therefore,
we also constructed a mutant luciferase reporter construct
where these nucleotides were deleted. Co-transfection of pcDNA3.1-2xFLAG-SREBP-1a (Toth et al., 2004) with the luciferase reporter containing the SUR2 promoter segment causes a three-fold increase in luciferase activity (Figure 4b), while co-transfection with the mutant luciferase reporter did not induce a significant increase in luciferase activity. Basal promoter activity was unaffected by the mutation (Figure 4c). These results indicate that the SUR2 promoter responds to activation of the SREBP signaling pathway, suggesting that SUR2 is a novel SREBP target gene.

3.5 | The SREBP inhibitor PF429242 suppresses the TSA-induced increase in SUR2 expression

Finally, to determine whether activation of SREBP signaling drives the increased SUR2 expression with TSA treatment, we used PF429242, a reversible competitive inhibitor that has previously been shown to reduce SREBP maturation (Hawkins et al., 2008; Sekar et al., 2017). PF429242 significantly inhibited the effect of TSA on SUR2 mRNA expression in a concentration-dependent manner (Figure 5), consistent with the conclusion that the increase in SUR2 expression following TSA treatment results from cholesterol depletion and SREBP activation.

4 | DISCUSSION

The present studies show that HDACi, like TSA, reduce cellular cholesterol activating a cholesterol-dependent mechanism that regulates expression of $K_{\text{ATP}}$ channel subunits. Indeed, the data show that the TSA-induced increase in SUR2 gene expression correlates with cellular cholesterol levels and that SREBP is cleaved and translocated to the nucleus. Moreover, we show that suppression of SREBP signaling with PF429242 significantly reduces the TSA-dependent increase in SUR2 expression. When coupled with data from luciferase reporter assays, these results demonstrate that cardiac $K_{\text{ATP}}$ subunit expression can be directly regulated by cholesterol-dependent activity of SREBP.

4.1 | Cholesterol and $K_{\text{ATP}}$ in the cardiovascular system

Elevated serum cholesterol is associated with poor cardiovascular health (Benjamin et al., 2019; Parish et al., 2012) and the development of hypertension (Halperin et al., 2006). Most consequences of high cholesterol are attributed to the development of arterial atherosclerotic plaques with consequent hypertension and increased risk for myocardial ischemia (Parish et al., 2012). Other findings associated
with hypercholesterolemia are not as easily attributable directly to atherosclerosis and suggest that excess cholesterol may inhibit the function or expression of $K_{\text{ATP}}$ channels. For example, hypercholesterolemia has been shown to impair ischemic preconditioning and the response to ischemia reperfusion (Csonka et al., 2014; Ferdinandy et al., 1997; Golino et al., 1987; Görbe et al., 2011; Kocić et al., 1999; Kyriakides et al., 2002; Maczewski & Maczewska, 2006; Osipov et al., 2009; Szilvassy et al., 1995; Ungi et al., 2005), both of which require the sarcolemmal $K_{\text{ATP}}$ (Cole et al., 1991; Du et al., 2006; Gross & Auchampach, 1992; Suzuki et al., 2002; Wojtovich et al., 2013). In addition, the cholesterol-reducing drug, simvastatin, reduces the no-reflow area following myocardial infarction through a $K_{\text{ATP}}$-dependent mechanism with an increase in SUR2 expression (Yang et al., 2007). Here, we present a possible explanation for this finding, where reduction in cellular cholesterol activates SREBP signaling and increases $K_{\text{ATP}}$ subunit expression. The present study is focused on cardiomyocytes, however, SUR2 is also a component of $K_{\text{ATP}}$ channels in vascular smooth muscle (Chutkow et al., 2002; Morrissey et al., 2005; Yoshida et al., 2004). Given the importance of $K_{\text{ATP}}$ in regulating blood pressure (Chutkow et al., 2002; Huang et al., 2018; Li et al., 2013; Miki et al., 2002), it is intriguing to speculate that cholesterol-dependent reduction in SUR2B expression in vascular smooth muscle contributes to the hypertensive phenotype associated with hypercholesterolemia.

### 4.2 Cholesterol and ion channel regulation

Cholesterol is critical component lipid of the cell membrane and there have been a number of studies examining...
the role of cholesterol in modulating ion channel function (Levitan et al., 2014). For example, cholesterol loading inhibits recombinant Kir2.1 channels expressed heterologously in CHO cells, while cholesterol depletion increases current (Romanenko et al., 2004). This appears to be due to direct interaction of cholesterol with residues in the cytoplasmic domain of the channel (Epshtein et al., 2009). Studies also show that targeting to cholesterol-enriched membrane domains is critical for normal regulation of KATP channel function by protein kinase A (Sampson et al., 2004). In the present study, we propose that cholesterol regulates ion channel subunit transcription through SREBP signaling. This is analogous to studies showing that Kir3.1 expression is increased in chick cardiomyocytes incubated in lipoprotein-depleted medium as a result of SREBP activation (Park et al., 2008). SREBP has principally been associated with regulating the genes required for fatty acid and cholesterol synthesis and transport, however, it is increasingly recognized that the importance of SREBP is not limited to lipid homeostasis (Jeon & Osborne, 2012; Shao & Espenshade, 2012). Indeed, the results presented here add to this growing body of literature linking cholesterol and SREBP signaling with nonmetabolic physiological outcomes.

4.3 | Cholesterol and arrhythmia

Increased K<sub>ATP</sub> activity accelerates repolarization, reduces the refractory period, and predisposes to re-entrant arrhythmias (Billman, 2008). It was recently demonstrated that trigger induced ventricular tachycardia or fibrillation during ischemia was significantly reduced in hypercholesterolemic mice (Ldlr<sup>−/−</sup> or ApoA1<sup>−/−</sup>) (Baartscheer et al., 2015). This result of that study is consistent with the present study indicating that cholesterol suppresses K<sub>ATP</sub> expression by inhibiting SREBP. Countering this observation, treatment with cholesterol-lowering statins is associated with reduced arrhythmia risk (Buber et al., 2012). K<sub>ATP</sub> channel activation can also stabilize the membrane potential and prevent triggered arrhythmias. It is possible that statin-induced cholesterol reduction increases K<sub>ATP</sub> expression to prevent arrhythmias, however, it is difficult to discern since statins are known to have pleiotropic effects variously attributed to modulation of nitric oxide synthase, Rho/ROCK kinase, Rac, and PPARs (Oesterle et al., 2017). Importantly, statins may affect other ion channels as well. For example, simvastatin has been shown to partially reverse the reduction in Kv4.3 expression in hypertrophic cardiomyocytes (Su et al., 2012). Nevertheless, the observation that K<sub>ATP</sub> expression can be regulated by cholesterol and SREBP signaling suggests another way in which hypercholesterolemia and statin therapy may affect the heart.

4.4 | HDACi-dependent depletion of cholesterol

TSA is a canonical HDACi that is known to increase histone acetylation generally and in HL-1 cardiomyocytes specifically (Fatima et al., 2015). In the present study, we show that TSA causes a time-dependent decrease in intracellular cholesterol. TSA has been previously shown to reduce cholesterol accumulation in mutant Neimann Pick Type C1 (NPC) fibroblasts and SH-SY5Y cells (Nunes et al., 2013; Pipalia et al., 2011). The mechanism underlying cholesterol depletion is not clear. In SH-SY5Y cells, it has been proposed that TSA modulates expression of cholesterol trafficking genes (Nunes et al., 2013). In addition, treatment of HepG2 cells with TSA causes reduced expression of 11 of the 15 genes involved in cholesterol biosynthesis suggesting an activation of SREBP signaling (Chittur et al., 2008). It remains unknown why TSA causes a reduction in cholesterol in HL-1 cardiomyocytes. In principle, TSA may increase cholesterol export, reduce cholesterol synthesis, or reduce cholesterol uptake. Interestingly, we do observe a significant (41-fold) upregulation of PCSK9. PCSK9 is a protease that serves as a chaperone for the LDLr causing it to be recycled from the plasma membrane and targeted for degradation (Joseph & Robinson, 2015). The use of PCSK9 inhibitors represents a new approach to lower cholesterol in patients with hypercholesterolemia, achieving significant reductions in circulating cholesterol by stabilizing LDLr in the hepatocyte membrane and increasing
cholesterol uptake (Sabatine, 2019). It remains unknown how TSA causes cholesterol depletion in HL-1 cells and additional studies will be needed to examine this interesting observation. Nevertheless, in the context of the present study, TSA is a potent molecular tool to deplete cellular cholesterol and reveals a novel cholesterol-dependent mechanism of $K_{\text{ATP}}$ subunit expression.

5 | CONCLUSION

In summary, the results demonstrate that TSA causes a reduction in cellular cholesterol that activates SREBP signaling and increases SUR2 expression. It is known that aggressive cholesterol-lowering therapies have significant benefit for patients with cardiovascular disease. We postulate that cholesterol lowering therapies would increase $K_{\text{ATP}}$ as one of the many beneficial effects on the cardiovascular system. Moreover, because $K_{\text{ATP}}$ channels protect the heart during metabolic stress, patients with hypercholesterolemia may not only be both more likely to experience an ischemic event due to atherosclerosis, but less able to cope with the ischemic event due to reduced $K_{\text{ATP}}$ expression in the heart.

DISCLOSURE

The opinions and assertions expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Uniformed Services University or the Department of Defense. Neither I nor my family members have a financial interest in any commercial product, service, or organization providing financial support for this research.

AUTHOR CONTRIBUTIONS

RG designed and performed experiments, analyzed the data, drafted and edited the manuscript. NF performed experiments and edited the manuscript. JFS maintained HL-1 cells. JTS assisted with the design and analysis of imaging experiments. MCH assisted in data analysis and edited manuscript. TPF designed experiments, analyzed data, and edited the manuscript. All authors have read and approved the final manuscript.

ORCID

Thomas P. Flagg https://orcid.org/0000-0002-3147-4060

REFERENCES

Baartscheer, A., Schumacher, C. A., Wekker, V., Verkerk, A. O., Veldkamp, M. W., van Oort, R. J., Elzenaar, I., Ottenhoff, R., van Roomen, C., Aerts, H., & Cornel, R. (2015). Dyscholesterolemia protects against ischemia-induced ventricular arrhythmias.
Physiology-Heart and Circulatory Physiology, 306, H405–H413. https://doi.org/10.1152/ajpheart.00257.2013

Du, Q., Jovanović, S., Clelland, A., Sukhodub, A., Budas, G., Phelan, K., Murray-Tait, V., Malone, L., & Jovanović, A. (2006). Overexpression of SUR2A generates a cardiac phenotype resistant to ischemia. The FASEB Journal, 20, 1131–1141. https://doi.org/10.1096/fj.05-5483com

Elcarpio, J. O. B. D., Ahinski, A. N. B., Zzo, N. I. J. I., Claycomb, W. C., Lanson, N. A., Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A., & Izzo, N. J. (1998). HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proceedings of the National Academy of Sciences of the United States of America, 95, 2979–2984.

Epshtein, Y., Chopra, A. P., Rosenhouse-Dantsker, A., Kowalsky, G. B., Logothetis, D. E., & Levitan, I. (2009). Identification of a C-terminus domain critical for the sensitivity of Kir2.1 to cholesterol. Proceedings of the National Academy of Sciences of the United States of America, 106, 8055–8060. https://doi.org/10.1073/pnas.0809847106

Fatima, N., Cohen, D. C., Sukumar, G., Sissung, T. M., Schooley, J. F. Jr, Haigney, M. C., Claycomb, W. C., Cox, R. T., Dalgard, C. L., Bates, S. E., & Flagg, T. P. (2015). Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis. Frontiers in Pharmacology, 6, 168. https://doi.org/10.3389/fphar.2015.00168

Fatima, N., Schooley, J. F., Claycomb, W. C., & Flagg, T. P. (2012). Promoter DNA methylation regulates murine SUR1 (Abcc8) and SUR2 (Abcc9) expression in HL-1 cardiomyocytes. PLoS One, 7, 1–10. https://doi.org/10.1371/journal.pone.0041533

Ferdinandy, P., Szilvássy, Z., Horváth, L. I., Csont, T., Csonka, C., Nagy, E., Szentgyörgyi, R., Nagy, I., Koltai, M., & Dux, L. (1997). Loss of pacing-induced preconditioning in rat hearts: Role of nitric oxide and cholesterol-enriched diet. Journal of Molecular and Cellular Cardiology, 29, 3321–3333. https://doi.org/10.1006/jmcc.1997.0557

Flagg, T. P., Enketchakul, D., Koster, J. C., & Nichols, C. G. (2010). Muscle K ATP channels: Recent insights to energy sensing and myoxygenation. Physiological Reviews, 90, 799–829. https://doi.org/10.1152/physrev.00207.2009

Flagg, T. P., Kurata, H. T., Masia, R., Caputa, G., Magnuson, M. A., Lefer, D. J., Coetzee, W. A., & Nichols, C. G. (2008). Differential structure of atrial and ventricular KATP: Atrial KATP channels require SUR1. Circulation Research, 103, 1458–1465. https://doi.org/10.1161/CIRCRESAHA.108.178186

Foster, M. N., & Coetzee, W. A. (2016). K ATP channels in the cardiovascular system. Physiological Reviews, 96, 177–252. https://doi.org/10.1152/physrev.00003.2015

Golino, P., Maroko, P. R., & Carew, T. E. (1987). Efficacy of platelet depletion in counteracting the detrimental effect of acute hypercholesterolemia on infant size and the neo-reflow phenomenon in rabbits undergoing coronary artery occlusion-reperfusion. Circulation, 76, 173–180.

Görbe, A., Varga, Z. V., Kupai, K., Bencsik, P., Kocsis, G. F., Csont, T., Boengler, K., Schulz, R., & Ferdinandy, P. (2011). Cholesterol diet leads to attenuation of ischemic preconditioning-induced cardiac protection: The role of connexin 43. American Journal of Physiology-Heart and Circulatory Physiology, 300, H1907–H1913. https://doi.org/10.1152/ajpheart.01242.2010

Gross, G. J., & Auchampach, J. A. (1992). Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circulation Research, 70, 223–233. https://doi.org/10.1161/01.RES.70.2.223

Halperin, R. O., Sesso, H. D., Ma, J., Buring, J. E., Stampfer, M. J., & Gaziano, J. M. (2006). Dyslipidemia and the risk of incident hypertension in men. Hypertension, 47, 45–50. https://doi.org/10.1161/01.HYP.0000196306.42418.0e

Hawkins, J. L., Robbins, M. D., Warren, L. C., Xia, D., Petras, S. F., Valentine, J. J., Varghese, A. H., Wang, I.-K., Subashi, T. A., Shelly, L. D., Hay, B. A., Landschulz, K. T., Geoghegan, K. F., & Harwood, H. J. (2008). Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. Journal of Pharmacology and Experimental Therapeutics, 326, 801–808. https://doi.org/10.1124/jpet.108.139626

Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002). SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation, 109, 1125–1131. https://doi.org/10.1172/JCI10021593

Huang, Y., McClennenagh, C., Harter, T. M., Hinman, K., Halabi, C. M., Matkovich, S. J., Zhang, H., Brown, G. S., Mecham, R. P., England, S. K., Kovacs, A., Remedi, M. S., & Nichols, C. G. (2018). Cardiovascular consequences of KATP overactivity in Canto syndrome. JCI Insight, 3, 1–16. https://doi.org/10.1172/jci.insight.121153

Huang, Y., Walker, K. E., Hanley, F., Narula, J., Houser, S. R., & Tulenko, T. N. (2004). Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation, 109, 97–102. https://doi.org/10.1161/01.CIR.0000109213.10461.F6

Hyun, J. J., Lee, H. S., Kim, K. S., Kim, Y. K., Yoon, D., & Sahng, W. P. (2008). Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. Journal of Lipid Research, 49, 399–409. https://doi.org/10.1194/jlr.M700443-JLR200

Jacobson, M. S., Ambudkar, I. S., Young, E. P., Naseem, S. M., Heald, F. P., & Shamoos, A. E. (1985). Cardiac sarcoplasmic reticulum Effects of an atherogenic diet during the neonatal and juvenile period. Atherosclerosis, 55, 81–91. https://doi.org/10.1016/0021-9150(85)90168-6

Jeon, T.-I., & Osborne, T. F. (2012). SREBP5: Metabolic integrators in physiology and metabolism. Trends in Endocrinology & Metabolism, 23, 65–72. https://doi.org/10.1016/j.tem.2011.10.004

Jeong, H. J., Lee, H.-S., Kim, K.-S., Kim, Y.-K., Yoon, D., & Park, S. W. (2008). Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. Journal of Lipid Research, 49, 399–409. https://doi.org/10.1194/jlr.M700443-JLR200

Joseph, L., & Robinson, J. G. (2015). Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Progress in Cardiovascular Diseases, 58, 19–31. https://doi.org/10.1016/j.pcad.2015.04.004

Kocić, I., Konstański, Z., Kaminski, M., Dworakowska, D., & Dworakowski, R. (1999). Experimental hyperlipidemia prevents the protective effect of ischemic preconditioning on the contractility and responsiveness to phenylephrine of rat-isolated stunned papillary muscle. General Pharmacology: the Vascular System, 33, 213–219. https://doi.org/10.1016/S0306-3623(99)00017-8
Kubota, I., Yamaki, M., Shibata, T., Ikeno, E., Hosoya, Y., & Tomoike, H. (1993). Role of ATP-sensitive K+ channel on EC-GST segment elevation during a bout of myocardial ischemia: A study on epicardial mapping in dogs. *Circulation*, 88, 1845–1851.

Kiyakides, Z. S., Psychari, S., Iliodromitis, E. K., Kolettis, T. M., Sbarouni, E., & Kremastinos, D. T. (2002). Hyperlipidemia prevents the expected reduction of myocardial ischemia on repeated balloon inflations during angioplasty. *Chest*, 121, 1211–1215. https://doi.org/10.1378/chest.121.4.1211

Lederer, W. J., & Nichols, C. G. (1989). Nucleotide modulation of the activity of rat heart ATP-sensitive K+ channels in isolated membrane patches. *The Journal of Physiology*, 419, 193–211. https://doi.org/10.1113/jphysiol.1989.sp017869

Leventhal, A. R., Chen, W., Tall, A. R., & Tabas, I. (2001). Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. *Journal of Biological Chemistry*, 276, 44976–44983. https://doi.org/10.1074/jbc.M106455200

Li, A., Knutsen, R. H., Zhang, H., Osei-Owusu, P., Moreno-Dominguez, A., Harter, T. M., Uchida, K., Remedi, M. S., Dietrich, H. B., Bernal-Mizrachi, C., Blumer, K. J., Mecham, R. P., Koster, J. C., & Nichols, C. G. (2013). Hypotension due to Kir6.1 gain-of-function in vascular smooth muscle. *Journal of the American Heart Association*, 2, 1–13. https://doi.org/10.1161/JAHA.113.000365

Li, R. A., Leppo, M., Miki, T., Seino, S., & Marbán, E. (2000). Molecular basis of electrocardiographic ST-segment elevation. *Circulation Research*, 87, 837–839.

Maczewski, M., & Maczewska, J. (2006). Hypercholesterolemia exacerbates ventricular remodeling in the rat model of myocardial infarction. *Journal of Cardiac Failure*, 12, 399–405. https://doi.org/10.1016/j.cardfail.2006.03.005

Magañ, M. M., & Osborne, T. F. (1996). Two tandem binding sites for 5-nucleotide modulation of the activity of rat heart ATP-sensitive K+ channels in isolated membrane patches. *The Journal of Physiology*, 419, 193–211. https://doi.org/10.1113/jphysiol.1989.sp017869

Maczewski, M., & Maczewska, J. (2006). Hypercholesterolemia exacerbates ventricular remodeling in the rat model of myocardial infarction. *Journal of Cardiac Failure*, 12, 399–405. https://doi.org/10.1016/j.cardfail.2006.03.005

Miki, T., Suzuki, M., Shibasaka, T., Uemura, H., Sato, T., Yamaguchi, K., Koseki, H., Iwanaga, T., Nakaya, H., & Seino, S. (2002). Mouse Kir6.1. *Journal of Biological Chemistry*, 277, 32689–32694. https://doi.org/10.1074/jbc.M106455200

Miki, T., Shibasaki, T., Uemura, H., Goto, S., Matsumoto, Y., Ikeno, E., Shibata, T., Ikeno, E., Hosoya, Y., & Tomoike, H. (2017). Pleiotropic effects of statins on the cardiovascular system. *Circulation Research*, 120, 229–243. https://doi.org/10.1161/CIRCRESAHA.116.308537

Osipov, R. M., Bianchi, C., Feng, J., Clements, R. T., Liu, Y., Robich, M. P., Glazer, H. P., Kodama, N. R., & Sellke, F. W. (2009). Effect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion. *Circulation*, 120, S22–S30. https://doi.org/10.1161/CIRCU LATIONAHA.108.842724

Parish, S., O'fer, A., Clarke, R., Hopewell, J. C., Hill, M. R., Otvos, J. D., Armitage, J., & Collins, R. (2012). Lipids and lipoproteins and risk of different vascular events in the MRC/BDH heart protection study. *Circulation*, 125, 2469–2478. https://doi.org/10.1161/CIRCULATI ONAHA.111.073684

Park, H. J., Georgescu, S. P., Du, C., Madia, C., Aronovitz, M. J., Welzig, C. M., Wang, B., Begley, U., Zhang, Y., Blausen, R. O., Pattan, R. D., Karas, R. H., Van Tol, H. H., Osborne, T. F., Shimano, H., Liao, R., Link, M. S., & Gaolper, J. B. (2008). Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. *Journal of Clinical Investigation*, 118, 259–271. https://doi.org/10.1172/JC132011

Phillip-Couderc, P., Tavares, N. I., Roati, A., Lerch, R., Montessuit, C., & Baertschi, A. J. (2008). Forkhead transcription factors coordinate expression of myocardial KATP channel subunits and energy metabolism. *Circulation Research*, 102, 20–35. https://doi.org/10.1161/CIRCRESAHA.107.166744

Pipalia, N. H., Cosner, C. C., Huang, A., Chatterjee, A., Bourbon, P., Farley, N., Helquist, P., Wiest, O., & Maxfield, F. R. (2011). Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. *Proceedings of the National Academy of Sciences of the United States of America*, 108, 5620–5625. https://doi.org/10.1073/pnas.1014890108

Romanenko, V. G., Fang, Y., Byfield, F., Travis, A. J., Vandenberg, C. A., Rothblat, G. H., & Levitan, I. (2004). Cholesterol sensitivity and lipid raft targeting of Kir2.1 channels. *Biophysical Journal*, 87, 3850–3861. https://doi.org/10.1529/biophysj.104.043273

Sabatine, M. S. (2019). PCSK9 inhibitors: Clinical evidence and implementation. *Nature Reviews Cardiology*, 16, 155–165. https://doi.org/10.1038/s41569-018-0107-8

Sampson, L. J., Hayabuchi, Y., Standen, N. B., & Dart, C. (2004). Caveolae localize protein kinase A signaling to arterial ATP-sensitive potassium channels. *Circulation Research*, 95, 1012–1018. https://doi.org/10.1161/01.RES.0000148634.47095.ab

Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V., Eliceiri, K., Tomancak, P., & Cardona, A. (2012). Fiji: An open-source platform for biological-image analysis. *Nature Methods*, 9(7), 676–682. https://doi.org/10.1038/nmeth.2019

Sekar, S., Gopalanarshvan, V., & Taghibiglou, C. (2017). Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. *Biochemical and Biophysical Research Communications*, 468, 136–140. https://doi.org/10.1016/j.bbrc.2017.05.023

Shao, W., & Esphenash, P. J. (2012). Expanding roles for SREBP in metabolism. *Cell Metabolism*, 16, 414–419. https://doi.org/10.1016/j.cmet.2012.09.002

Su, F., Shi, M., Yan, Z., Ou, D., Li, J., Lu, Z., & Zheng, Q. (2012). Simvastatin modulates remodeling of Kv4.3 expression in rat
hypertrophied cardiomyocytes. *International Journal of Biological Sciences*, 8, 236–248. https://doi.org/10.7150/ijbs.8.236

Suzuki, M., Li, R. A., Miki, T., Uemura, H., Sakamoto, N., Ohmotosekine, Y., Tamagawa, M., Ogura, T., Seino, S., Marbán, E., & Nakaya, H. (2001). Potassium channels clarified by Kir6.2-knockout mice. *Circulation Research*, 88, 570–577.

Suzuki, M., Sasaki, N., Miki, T., Sakamoto, N., Ohmotosekine, Y., Tamagawa, M., Seino, S., & Nakaya, H. (2002). Role of sarclemmal KATP channels in cardioprotection against ischemia/reperfusion injury in mice. *Journal of Clinical Investigation*, 109, 509–516. https://doi.org/10.1172/JCI20021470.

Introduction

Szilvassy, Z., Ferdinandy, P., Szilvassy, J., Nagy, I., Karcsu, S., Lonovics, J., Dux, L., & Koltai, M. (1995). The loss of pacing-induced preconditioning in atherosclerotic rabbits: Role of hypercholesterolaemia. *Journal of Molecular and Cellular Cardiology*, 27, 2559–2569. https://doi.org/10.1006/jmcc.1995.0043

Toth, J. I., Datta, S., Athanikar, J. N., Freedman, L. P., & Osborne, T. F. (2004). Selective coactivator interactions in gene activation by SREBP-1a and -1c. *Molecular and Cellular Biology*, 24, 8288–8300. https://doi.org/10.1128/mcb.24.18.8288-8300.2004

Ungi, I., Ungi, T., Ruzsa, Z., Nagy, E., Zimmermann, Z., Csont, T., & Ferdinandy, P. (2005). Hypercholesterolaemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. *Chest*, 128, 1623–1628. https://doi.org/10.1378/chest.128.3.1623

Wang, X., Sato, R., Brown, M. S., Hua, X., & Goldstein, J. L. (1994). SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. *Cell*, 77, 53–62. https://doi.org/10.1016/0092-8674(94)90234-8

Wojtovich, A. P., Urciuoli, W. R., Chatterjee, S., Fisher, A. B., Nehrke, K., & Brookes, P. S. (2013). Kir6.2 is not the mitochondrial KATP channel but is required for cardioprotection by ischemic preconditioning. *American Journal of Physiology-Heart and Circulatory Physiology*, 304, 1439–1445. https://doi.org/10.1152/ajpheart.00972.2012

Yang, Y. J., Zhao, J. L., You, S. J., Wu, Y. J., Jing, Z. C., Gao, R. L., & Chen, Z. J. (2007). Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel. *European Journal of Heart Failure*, 9, 30–36. https://doi.org/10.1016/j.ejheart.2006.04.013

Yokoyama, C., Wang, X., Briggs, M. R., Admon, A., Wu, J., Hua, X., Goldstein, J. L., & Brown, M. S. (1993). SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. *Cell*, 75, 187–197. https://doi.org/10.1016/0092-8674(93)90095-9

Yoshida, H., Feig, J. E., Morrissey, A., Ghiu, I. A., Artman, M., & Coetzee, W. A. (2004). KATP channels of primary human coronary artery endothelial cells consist of a heteromultimeric complex of Kir6.1, Kir6.2, and SUR2B subunits. *Journal of Molecular and Cellular Cardiology*, 37, 857–869. https://doi.org/10.1016/j.yjmcc.2004.05.022

How to cite this article: Geiger R, Fatima N, Schooley JF, Smyth JT, Haigney MC, Flagg TP. Novel cholesterol-dependent regulation of cardiac $K_{\text{ATP}}$ subunit expression revealed using histone deacetylase inhibitors. *Physiol Rep*, 2020;8:e14675. https://doi.org/10.14814/phy2.14675